Apimeds Pharmaceuticals US (APUS) Intangibles (2025 - 2026)
Apimeds Pharmaceuticals US's (APUS) quarterly Intangibles came in at $116.7 million in Q2 2026, down 22.12% quarter-over-quarter from $149.9 million in Q4 2025.
Powered by 
Analysis
Apimeds Pharmaceuticals US (APUS) Intangibles (2025 - 2026) Analysis & Trends
Apimeds Pharmaceuticals US (APUS) has reported Intangibles for 2 consecutive years, with $116.7 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Intangibles changed N/A year-over-year to $116.7 million; the trailing twelve-month figure through Jun 2026 stood at $116.7 million (changed N/A YoY), and the FY2025 full-year result was $149.9 million, changed N/A from the prior year.
- Intangibles retreated to $116.7 million in Q2 2026 per APUS's latest filing, from $149.9 million in the prior quarter.
- Across five years, Intangibles topped out at $149.9 million in Q4 2025 and bottomed at $116.7 million in Q2 2026.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn | 20.49 Bn |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn | 14.03 Bn |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn | 412.80 Mn |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn | 1.31 Bn |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn | 266.00 Mn |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn | - |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn | 13.52 Bn |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn | 93.49 Mn |
| 10 | Apimeds Pharmaceuticals US | 3.65 Mn | 3.65 Mn | - | 116.74 Mn |